跨癌种循环蛋白预测肝恶性肿瘤局部消融预后
本研究为ESTIMATE试验的事后探索性分析,纳入103例接受间质近距离放疗的肝细胞癌、肝内胆管癌或乳腺/结直肠癌肝转移患者。采用免疫分析检测基线血浆蛋白,发现CCL20、IL-15、IL-8升高与不良预后相关,并构建免疫炎症预后模型。该模型预测总生存的AUC在6、12、18个月分别为0.70、0.72、0.74,乐观校正后为0.61至0.68。
要点
- CCL20、IL-15、IL-8升高提示肝恶性肿瘤消融后预后不良
- 免疫炎症模型可辅助筛选适合局部消融的肝肿瘤患者
- 该蛋白组合跨多个肝肿瘤类型具有预后价值
核心结论
- 研究发现一组跨癌种循环蛋白可预测肝恶性肿瘤局部消融后的治疗反应和预后。
研究设计与样本
- 研究类型为ESTIMATE前瞻性对照试验的事后探索性分析,德国临床试验注册号DRKS 00010587。
- 共纳入103例患者,其中62例男性,平均年龄67.5岁,范围36-87岁。
- 研究对象为2017至2023年间接受间质近距离放疗的肝细胞癌、肝内胆管癌或乳腺/结直肠癌肝转移患者。
- 采用免疫分析panel检测基线血浆样本。
- 生存分析采用Kaplan-Meier、log-rank和Cox回归,多变量Cox模型校正肿瘤类型、病灶数量和治疗反应。
诊断标准与关键数值
- 免疫炎症预后模型预测总生存的AUC在6个月为0.70,12个月为0.72,18个月为0.74。
- 经bootstrap重采样估计乐观校正后的模型性能为0.61至0.68。
临床应用与阅片要点
- 基线检测CCL20、IL-15、IL-8有助于在消融前识别预后较差的患者。
- 该蛋白组合可作为跨肝细胞癌、胆管癌及肝转移瘤的通用预后参考。
局限性
- 本研究为事后探索性分析,样本量仅为103例。
- 乐观校正后AUC降至0.61至0.68,提示模型独立验证性能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To identify a panel based on circulating proteins to predict clinical outcomes after local ablation across patients with primary and metastatic liver cancer to improve patient selection. Materials and Methods This exploratory post hoc analysis is derived from ESTIMATE, a prospective controlled trial (DRKS registration no. 00010587) evaluating progression-free survival and overall survival (OS) after local ablation of liver malignancies between 2017 and 2023. Baseline plasma samples from patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or metastatic breast or colorectal cancer treated with interstitial brachytherapy were profiled using an immunoassay panel. Group comparisons used t tests or Mann-Whitney U tests. Survival was assessed using Kaplan-Meier, log-rank, and Cox regression analyses. Multivariable Cox models were adjusted for tumor type, number of lesions, and treatment response. Model discrimination was assessed using time-dependent areas under the receiver operating characteristic curves (AUCs) for OS, with bootstrap resampling used to estimate optimism-corrected performance. Results In total, 103 patients (62 male; mean age, 67.5 years; range, 36-87 years) were included. Elevated chemokine (C-C motif) ligand 20, interleukin-15, and interleukin-8 levels were associated with poor clinical outcomes across various liver tumors and were therefore incorporated into an immune-inflammatory prognostic model (all P < .05). AUC analysis revealed the predictive accuracy of the model for OS at 6, 12, and 18 months (AUCs: 0.70, 0.72, and 0.74, respectively), and bootstrap optimism-corrected performance ranged from 0.61 to 0.68. Conclusion The findings revealed a cross-cancer panel of circulating proteins that reliably and effectively predicts treatment response and prognosis after local ablation of liver malignancies. Keywords: Prognosis & Prediction, Treatment Response Assessment, Ablation Techniques, Interventional Oncology, Molecular Imaging-Clinical Translation, Molecular Imaging-Cancer, Liquid Biopsy, Abdomen/GI, Decision Analysis, Evidence-based Medicine, Outcomes Analysis, Liver Cancer, Interstitial Brachytherapy, Cross-Cancer Biomarkers, Proximity Extension Assay German Clinical Trials Register no. DRKS 00010587 Supplemental material is available for this article. © RSNA, 2026.
引用
- Nardone, Öcal, Salvermoser, et al. Cross-Cancer Circulating Proteins for the Prognosis of Primary and Metastatic Liver Cancer Treated with Local Ablation: Post Hoc Exploratory Analysis of the ESTIMATE Trial. Radiol Imaging Cancer. 2026. PMID: 42429582. doi:10.1148/rycan.250685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。